STAFF INVESTIGATORS: AYTEKIN OTO, M.D.
调查人员:AYTEKIN OTO,医学博士
基本信息
- 批准号:8486670
- 负责人:
- 金额:$ 1.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-01 至 2018-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvanced Malignant NeoplasmAdvisory CommitteesApplications GrantsCancer BiologyCancer Center Support GrantChicagoClinicalClinical InvestigatorClinical ManagementClinical ResearchClinical TrialsClinical Trials DesignCollaborationsComprehensive Cancer CenterContrast MediaDevelopmentDiagnosisDoctor of MedicineFacultyFundingHealthImageImage AnalysisImaging TechniquesImaging technologyIndividualInstructionLaboratoriesLeadMalignant NeoplasmsMedicalMedicineMethodologyMethodsModalityOutcomePatientsPlayPositioning AttributePublicationsRadiology SpecialtyRecommendationResearchResearch InfrastructureResearch PersonnelResource SharingResourcesRiskScienceScientistStrategic PlanningTestingTherapeuticTranslational ResearchUniversitiesWorkbasecancer carecancer therapydiagnostic accuracyimaging modalityimprovedinnovationpreventprogramsresearch clinical testingresponseworking group
项目摘要
. Based on the previous CCSG review (2007), the recommendations of our External Advisory Committee, and our strategic planning efforts, the UCCCC has identified the expansion of basic, clinical, and translational imaging research as a high priority. To expand our imaging research and improve the clinical management of cancer, the Advanced Imaging Program (Al) has undergone significant restructuring. Specifically, a high priority has been placed on the integration of imaging and imaging analysis methodology into clinical trials to evaluate new therapies and contrast agents, as well as developing and testing new imaging methods. CCSG funds are requested to support one Staff Investigator, Dr. Aytekin Oto, to spearhead these efforts. The Staff Investigator will work closely with the Imaging Working Group, UCCCC senior leaders, and existing or developing Shared Resources, and the Department of Radiology modality-specific laboratories to facilitate translational and clinical imaging research.
.根据之前的CCSG审查(2007年),我们的外部咨询委员会的建议,以及我们的战略规划工作,UCCCC已经确定了基础,临床和转化成像研究的扩展作为一个高度优先事项。为了扩大我们的成像研究和改善癌症的临床管理,高级成像计划(Al)经历了重大重组。特别是,高度重视将成像和成像分析方法整合到临床试验中,以评估新的治疗方法和造影剂,以及开发和测试新的成像方法。请求CCSG提供资金,以支持一名工作人员调查员Aytekin Oto博士带头开展这些工作。研究人员将与成像工作组,UCCCC高级领导人,现有或正在开发的共享资源以及放射科特定模式实验室密切合作,以促进转化和临床成像研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHELLE M LE BEAU其他文献
MICHELLE M LE BEAU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHELLE M LE BEAU', 18)}}的其他基金
Molecular mechanisms of myeloid suppressor genes on chromosome 5
5号染色体骨髓抑制基因的分子机制
- 批准号:
8997482 - 财政年份:2015
- 资助金额:
$ 1.83万 - 项目类别:
Molecular mechanisms of myeloid suppressor genes on chromosome 5
5号染色体骨髓抑制基因的分子机制
- 批准号:
8797860 - 财政年份:2015
- 资助金额:
$ 1.83万 - 项目类别:
Registration and Submission of Clinical Trials Data
临床试验数据的注册和提交
- 批准号:
8744809 - 财政年份:2014
- 资助金额:
$ 1.83万 - 项目类别:














{{item.name}}会员




